1887
Volume 2012, Issue 1
  • ISSN: 1999-7086
  • E-ISSN: 1999-7094

Abstract

Abstract

Safety data on recombinant activated factor VII (rFVIIa, NovoSeven; Novo Nordisk A/S, Bagsværd, Denmark) in actively hemorrhaging trauma patients are limited. We present detailed safety data from a large multicenter, randomized, placebo-controlled phase III study (the CONTROL trial). Data from 560 patients were analyzed. Subjects were monitored for adverse events (AEs) after rFVIIa or placebo administration. Incidences, timing, and presence of risk factors were reported by site investigators, supported by external study monitors and overseen by an independent Data Monitoring Committee. There were no differences in overall mortality, organ system failure, or AEs, serious AEs, or medical events of special interest. Arterial and venous thromboembolic (TE) events and their risk factors were similar in both groups. The greatest risk factor for TE events was a chest injury requiring mechanical ventilation >3 days (86%). There were four site investigator-reported myocardial infarctions in the rFVIIa group of which only one met diagnostic criteria preestablished by the Data Monitoring Committee. There were no reported myocardial infarctions in the placebo group. Troponins were increased in 30% of all patients. The rate of acute respiratory distress syndrome was lower in the rFVIIa (3.0%) than in the placebo (7.2%) group (). This represents the largest placebo-controlled dataset of rFVIIa use in trauma patients to date. In this prospective study of critically bleeding trauma patients, rFVIIa use was associated with an imbalance of investigator-reported Acute myocardial infarction/non-ST segment elevation myocardial infarction (AMI/NSTEMI), but was not associated with an increased risk for other AEs, including TE complications.

Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2012.18
2012-09-19
2019-08-18
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2012/1/jemtac.2012.18.html?itemId=/content/journals/10.5339/jemtac.2012.18&mimeType=html&fmt=ahah

References

  1. [1]. Spahn   D.R., , Cerny   V., , Coats   T.J.   et al. Management of bleeding following major trauma: a European guideline. . Crit Care . 2007; ;11: : R17 .
    [Google Scholar]
  2. [2]. Tieu   B.H.., , Holcomb   J.B.., and Schreiber   M.A..   Coagulopathy: its pathophysiology and treatment in the injured patient. . World JSurg . 2007; ;31: : 1055– 1064 .
    [Google Scholar]
  3. [3]. Kenet   G., , Walden   R., , Eldad   A.   et al. Treatment of traumatic bleeding with recombinant factor VIIa. . Lancet . 1999 Nov27; ;354: : 9193 , 1879 .
    [Google Scholar]
  4. [4]. Hauser   Carl J., , Boffard   Kenneth, , Dutton   Richard   et al. Results of the CONTROL Trial: Efficacy and Safety of Recombinant ActivatedFactor VII in the Management of Refractory Traumatic Hemorrhage. . The Journal ofTrauma, Injury, Infection, and Critical Care . September 2010; ;69: : 3 , 489– 500 .
    [Google Scholar]
  5. [5]. Dutton   Richard, , Hauserb   Carl, , Boffard   Kenneth   et al. Scientific and logistical challenges in designing the CONTROL trial: recombinantfactor VIIa in severe trauma patients with refractory bleeding. . Clinical Trials . 2009; ;0: : 1– 13 .
    [Google Scholar]
  6. [6]. Neal   Matthew D., , Hoffman   Marcus K., , Cuschieri   Joseph   et al. Crystalloid to packed red blood cell transfusion ratio in the massively transfusedpatient: When a little goes a long way. . J Trauma . 2012; ;72: : 4 , 892– 898 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/jemtac.2012.18
Loading
  • Article Type: Other
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error